The supplied filings document one Revvity, Inc. premarket notification: K262893 for the Eonis™ SMA kit, received August 17, 2026, and decided September 30, 2026, with decision code SESE and the description Substantially Equivalent. The FDA record lists Revvity, Inc. at 77 4th Ave., Waltham, MA, with Lisa Vershave as contact, and classifies the device as a Class II Spinal Muscular Atrophy Newborn Screening Test System under product code QUE and regulation 866.5980, in the Immunology panel. The decision summary states the purpose of submission as adding a new instrument to the test system and names Survival Motor Neuron 1 (SMN1) as the measurand. [1][2]
What the clearance covers
K262893 is a Traditional 510(k) with no third-party review, a Summary statement, and an advisory committee recorded as Immunology, with the review advisory committee listed as CH. The decision summary frames the submission as an instrument addition to an existing test system rather than a new assay, and identifies SMN1 as the measurand. The FDA record carries device class 2, regulation number 866.5980, product code QUE, and the device name Spinal Muscular Atrophy Newborn Screening Test System. [1][2]
The decision summary describes retesting of routine newborn screening specimens with initial presumptive positive results on both the candidate and predicate devices, and notes that confirmed positive specimens were not retested because of limited quantities available. That passage describes the comparison design in the review document; it does not report performance results. [2]
The Eonis product line as published
Revvity's product page describes the Eonis™ SCID-SMA kit as intended for semi-quantitative determination of TREC and KREC and qualitative detection of the exon 7 SMN1 gene and RPP30 gene in DNA from blood specimens dried on filter paper, as an aid in newborn screening. The same page describes it as a PCR kit for quantitative determination of Severe Combined Immunodeficiency and x-linked Agammaglobulinemia alongside qualitative detection of Spinal Muscular Atrophy using newborn dried blood spot samples. [4]
A Revvity Japan page for the Eonis System states that multiplexing of SMA, SCID and XLA screening can be done in one assay using Real-Time PCR technology without increasing daily hands-on workload and complexity. That statement is published by Revvity on its Japanese site and describes the platform, not the K262893 decision. [7]
Earlier clearance and corporate naming
An earlier clearance letter, K203035 dated November 9, 2022, names PerkinElmer Inc as the applicant for the Eonis SCID-SMA kit under regulation 21 CFR 866.5930, the newborn screening test for severe combined immunodeficiency disorder, Class II, product code PJI. The letter is addressed to a PerkinElmer regulatory affairs contact at 940 Winter St, Waltham, MA. The public documents do not state a corporate relationship between PerkinElmer and Revvity, so any link between the two applicants is not established here. [8]
Revvity's own site describes the company as bringing together AI-powered informatics, automation, reagents, imaging, analytical technologies and scientific expertise for connected Lab-in-the-Loop workflows, and carries a trademark notice for Revvity, Inc. Those are publisher statements about the company's positioning, not regulatory findings. [5]
Disease context and collection scope
Revvity's SMA disorder page describes spinal muscular atrophy as a neuromuscular disease inherited in an autosomal recessive manner, characterized by muscle weakness and atrophy from progressive degeneration and loss of lower motor neurons in the spinal cord and brain stem nuclei, with onset ranging from before birth to adolescence or young adulthood. The page is educational background published by Revvity. [6]
The supplied portfolio snapshot, retrieved November 20, 2026, contains one linked record, a 510(k) with decision SESE, and the record sample holds that single entry, K262893. The decision counts and sample decision counts both show one SESE decision, so the sample equals the full supplied collection; this is a snapshot of supplied filings, not a measure of company sales, total portfolio or safety performance. A separate openFDA query for decision dates from September 28 to December 31, 2026 returned 67 results in total, a broader device-wide set that is not specific to Revvity. [1][9]

